Small molecular weight enzyme inhibitors; imaging and drug delivery

Cancer Targeted Technology (CTT) is focused on developing innovative small molecule drugs specifically designed for the diagnosis and treatment of prostate cancer. One of their key products, CTT1057, is an 18F-labeled PET imaging agent that allows for rapid imaging of prostate cancer within two hours of administration. This agent is particularly effective in detecting cancer that has metastasized beyond the prostate, including bone metastases, with greater precision than current diagnostic methods. CTT1057 targets the Prostate Specific Membrane Antigen (PSMA), a biomarker that is over-expressed in most prostate cancer cells, thereby enhancing the accuracy of diagnosis and treatment planning for patients.

In addition to CTT1057, CTT is also developing CTT1403, a novel radiotherapeutic drug that serves as a companion treatment to the imaging agent. CTT1403 is designed to bind irreversibly to PSMA-expressing tumor cells, providing targeted therapy for prostate cancer. The combination of CTT1057 and CTT1403 represents a theranostic approach, allowing for both diagnosis and treatment of prostate cancer in a coordinated manner. CTT's advancements in these technologies are supported by clinical trials and collaborations with major pharmaceutical companies, highlighting their commitment to improving cancer care through targeted therapies.

United States

CancerTargetedTechnology develops innovative agents for cancer that accurately detect early and advanced disease, monitor treatment efficacy

Cancer Targeted Technology

Company Details